



November 28, 2022

Company Name: AnGes Inc.

Presentative: Ei Yamada, President & CEO

**Notice of decision to subscribe for convertible bonds
issued by MyBiotics Pharma Ltd.**

AnGes, Inc. announces its decision to subscribe for convertible bonds issued by Israeli biotech company MyBiotics Pharma Ltd (MyBiotics).

Although this matter is not subject to timely disclosure as stipulated by the Tokyo Stock Exchange, we are voluntarily disclosing this information because we believe it is useful information.

1. Outline of Convertible Bonds

Issuing Company	MyBiotics Pharma Ltd. (Israel: Representative Didi Daboush)
Amount	500,000USD
Implementation Date	November 28 , 2022
Use of funds	Research and development expenses
Type of shares after conversion	Highest priority of shares outstanding at time of conversion

2. About MyBiotics

MyBiotics is a pioneer in the field of next-generation pharmaceutical research and development in the study of the microbiome, the ecosystem of microorganisms in the body, which is attracting a great deal of attention worldwide.

MyBiotics is the first company in the world to develop a technology for cultivating and formulating indigenous bacteria, including intestinal bacteria, while maintaining the ratio of the various types of bacteria that make up the microbiome, and improving their quality, survival and viability rate in the intestines. This is an important technology essential for the practical application of microbiome medicine, and the company has a high advantage in the race to commercialize the microbiome.

Among MyBiotics's pipeline of development products, the company has already signed licensing agreements with major pharmaceutical companies to commercialize products for gastrointestinal and gynecological diseases. MBX-SD-202, which MyBiotics is developing as an investigational drug for recurrent and severe *Clostridium difficile* infection after antibiotic treatment, completed a Phase I clinical trial in healthy volunteers in Israel in January 2022, with positive results.

MyBiotics plans to use the proceeds from the convertible bond financing to prepare for Phase II-A clinical trials of the product in the U.S..

(Note) This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.



3. Future outlook

The impact of the subscription of the convertible bonds on our consolidated financial results for the fiscal year ending December 31, 2022 is expected to be immaterial. We will promptly announce any matters that should be disclosed in the future.

By subscribing to the convertible bonds, AnGes will support the research and development of microbiome medicines at MyBiotics and will consider future in-licensing of microbiome medicines.